Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Neurology · Autosomal Dominant Alzheimer Disease

The Blueprint of Disease: Genetics and Biology of ADAD

At a Glance

Autosomal Dominant Alzheimer Disease (ADAD) is primarily caused by a mutation in the APP, PSEN1, or PSEN2 genes. Because it is an autosomal dominant condition, a child of an affected parent has a 50% chance of inheriting the mutation, which leads to early-onset Alzheimer's.

To understand Autosomal Dominant Alzheimer Disease (ADAD), it helps to look at the brain as a complex factory. In this factory, certain “blueprints” (genes) provide instructions for creating proteins. In ADAD, a single typo in one of these blueprints causes the factory to produce a sticky, toxic byproduct that eventually disrupts the entire system.

The Three Key Blueprints: APP, PSEN1, and PSEN2

Almost all cases of ADAD are caused by a mutation in one of three specific genes. Each plays a role in how the brain handles a protein called amyloid-beta [1][2].

  • APP (Amyloid Precursor Protein): This gene provides the instructions for the “source protein.” In a healthy brain, APP helps with the growth and repair of nerve cells [3][4]. However, when this gene has a mutation, it can cause the body to produce too much amyloid-beta or a version that is especially prone to clumping [5].
  • PSEN1 (Presenilin 1): This is the most common site for ADAD mutations [6]. PSEN1 is part of a “molecular scissor” called gamma-secretase. Its job is to cut the APP protein into smaller pieces. A mutation here acts like a pair of faulty scissors that makes the wrong cuts, creating longer, stickier versions of amyloid-beta that the brain cannot easily clear [7][8].
  • PSEN2 (Presenilin 2): Similar to PSEN1, this gene is also part of the “molecular scissors.” Mutations in PSEN2 are rarer and often lead to a slightly later age of onset compared to PSEN1 [9][6].

The 50/50 Rule: Autosomal Dominant Inheritance

The term autosomal dominant describes how the disease is passed from parent to child:

  • Autosomal means the gene is located on one of the numbered chromosomes (not the sex chromosomes), so it affects men and women equally.
  • Dominant means you only need one copy of the mutated gene (from one parent) to develop the disease.

If a parent carries an ADAD mutation, every child they have has a 50% chance of inheriting that mutation [10]. If a child does not inherit the mutation, they cannot pass it on to their own children. In ADAD, the “penetrance” is nearly 100%, meaning that anyone who inherits the mutation will almost certainly develop the disease, usually at a predictable age [2].

The Biological “Chain Reaction”

The progression of ADAD is often described by the amyloid cascade hypothesis. This theory suggests that the disease follows a specific, predictable sequence [11][12]:

  1. Amyloid-Beta Clumping: Because of the genetic “typo,” amyloid-beta begins to stick together, forming plaques outside of nerve cells [5][13].
  2. Inflammation: These plaques trigger the brain’s immune cells (microglia), causing inflammation that further damages brain tissue [12].
  3. Tau Tangles: The buildup of amyloid eventually triggers a second protein called tau. In a healthy brain, tau acts like railroad ties that keep nerve cell tracks straight. In ADAD, tau collapses into tangles inside the cells, causing the cells to die [12][13].
  4. Symptoms: It is usually the formation of these tau tangles and the resulting cell death—not the initial amyloid plaques—that lead to the first symptoms of memory loss and cognitive decline [14].

Predicting the Future: Mutation and Onset

One of the most striking features of ADAD is the “consistency of onset.” Within a specific family, the age when symptoms start is usually very similar from one generation to the next [2].

While the general “clumping” process is the same, the location of the mutation within the gene can change the disease’s “flavor.” For example, certain mutations in the PSEN1 gene are associated with specific symptoms like spastic paraparesis (stiffness in the legs) or even early psychiatric symptoms that can be misdiagnosed [15][16].

Researchers have also discovered rare cases where people with an ADAD mutation did not get sick until much later. Mutations like the APOE3 Christchurch variant seem to protect the brain by slowing down the spread of tau tangles, even when amyloid levels are high [17][18]. These “resilient” individuals are currently providing vital clues for developing new treatments for everyone [19][20].

Common questions in this guide

What genes cause Autosomal Dominant Alzheimer Disease?
Almost all cases of ADAD are caused by a single mutation in one of three specific genes: APP, PSEN1, or PSEN2. These genetic changes disrupt how the brain processes a protein called amyloid-beta, leading to toxic buildup.
What is the chance of inheriting an ADAD mutation?
Because ADAD follows an autosomal dominant inheritance pattern, a child of a parent with the mutation has a 50% chance of inheriting it. If a person inherits the mutated gene, they will almost certainly develop the disease.
What is the amyloid cascade hypothesis?
This theory explains the biological chain reaction of the disease. It suggests that amyloid-beta proteins clump together into plaques, which causes brain inflammation and triggers the formation of toxic tau tangles. It is these tau tangles that eventually cause nerve cells to die and memory loss symptoms to begin.
Is the age when ADAD symptoms start predictable?
Within a specific family, the age when ADAD symptoms begin is usually very consistent from one generation to the next. The specific gene involved and the exact location of the mutation heavily influence this timeline.
Can protective genes delay early-onset Alzheimer's symptoms?
While very rare, researchers have discovered people with an ADAD mutation who did not develop symptoms until much later in life. This is often due to rare protective genetic variants, like the APOE3 Christchurch mutation, which slow down brain damage and are currently being studied for new treatments.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which specific mutation has been identified in my family, and in which gene (PSEN1, PSEN2, or APP)?
  2. 2.How does the location of my family's mutation typically influence the age of symptom onset or the types of symptoms seen?
  3. 3.Can you explain the current understanding of the 'amyloid cascade' and how it might be targeted by new clinical trial medications?
  4. 4.Are there any known 'protective factors' or variants, like the Christchurch mutation, that researchers are currently studying in relation to my family's gene?
  5. 5.What is the difference between a 'pathogenic' mutation and a 'variant of unknown significance' if my test results are not clear?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (20)
  1. 1

    Evaluating pathogenicity of variants of unknown significance in APP, PSEN1, and PSEN2.

    Marsh JA, Huang G, Bowling K, et al.

    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2025; (22(3)):e00527 doi:10.1016/j.neurot.2025.e00527.

    PMID: 39875235
  2. 2

    Positron emission tomography and magnetic resonance imaging methods and datasets within the Dominantly Inherited Alzheimer Network (DIAN).

    McKay NS, Gordon BA, Hornbeck RC, et al.

    Nature neuroscience 2023; (26(8)):1449-1460 doi:10.1038/s41593-023-01359-8.

    PMID: 37429916
  3. 3

    APP-Mediated Signaling Prevents Memory Decline in Alzheimer's Disease Mouse Model.

    Deyts C, Clutter M, Pierce N, et al.

    Cell reports 2019; (27(5)):1345-1355.e6 doi:10.1016/j.celrep.2019.03.087.

    PMID: 31042463
  4. 4

    APP Receptor? To Be or Not To Be.

    Deyts C, Thinakaran G, Parent AT

    Trends in pharmacological sciences 2016; (37(5)):390-411 doi:10.1016/j.tips.2016.01.005.

    PMID: 26837733
  5. 5

    An APP ectodomain mutation outside of the Aβ domain promotes Aβ production in vitro and deposition in vivo.

    Zhang X, Zhang CM, Prokopenko D, et al.

    The Journal of experimental medicine 2021; (218(6)) doi:10.1084/jem.20210313.

    PMID: 33822840
  6. 6

    Genetics of dementia: insights from Latin America.

    Ramos C, Aguillon D, Cordano C, Lopera F

    Dementia & neuropsychologia 2020; (14(3)):223-236 doi:10.1590/1980-57642020dn14-030004.

    PMID: 32973976
  7. 7

    Presenilin: A Multi-Functional Molecule in the Pathogenesis of Alzheimer's Disease and Other Neurodegenerative Diseases.

    Sun Y, Islam S, Michikawa M, Zou K

    International journal of molecular sciences 2024; (25(3)) doi:10.3390/ijms25031757.

    PMID: 38339035
  8. 8

    Targeting γ-Secretase for Familial Alzheimer's Disease.

    Wolfe MS

    Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents 2021; (30(7)):1321-1327 doi:10.1007/s00044-021-02744-3.

    PMID: 35295247
  9. 9

    Quantitative comparison of presenilin protein expression reveals greater activity of PS2-γ-secretase.

    Eccles MK, Main N, Carlessi R, et al.

    FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2024; (38(1)):e23396 doi:10.1096/fj.202300954RR.

    PMID: 38156414
  10. 10

    An attractive alternative to prenatal diagnosis: a case report of preimplantation genetic testing in familial cardiomyopathy.

    Pandey S, Khandhedia P

    AJOG global reports 2025; (5(2)):100476 doi:10.1016/j.xagr.2025.100476.

    PMID: 40231191
  11. 11

    Do BACE inhibitor failures in Alzheimer patients challenge the amyloid hypothesis of the disease?

    Panza F, Lozupone M, Watling M, Imbimbo BP

    Expert review of neurotherapeutics 2019; (19(7)):599-602 doi:10.1080/14737175.2019.1621751.

    PMID: 31112433
  12. 12

    NLRP3 inflammasome activation drives tau pathology.

    Ising C, Venegas C, Zhang S, et al.

    Nature 2019; (575(7784)):669-673 doi:10.1038/s41586-019-1769-z.

    PMID: 31748742
  13. 13

    Testing the amyloid cascade hypothesis: Prevention trials in autosomal dominant Alzheimer disease.

    Levin J, Vöglein J, Quiroz YT, et al.

    Alzheimer's & dementia : the journal of the Alzheimer's Association 2022; (18(12)):2687-2698 doi:10.1002/alz.12624.

    PMID: 35212149
  14. 14

    Clinical and biomarker trajectories in sporadic Alzheimer's disease: A longitudinal study.

    Wang HF, Shen XN, Li JQ, et al.

    Alzheimer's & dementia (Amsterdam, Netherlands) 2020; (12(1)):e12095 doi:10.1002/dad2.12095.

    PMID: 32793801
  15. 15

    Spastic paraplegia preceding PSEN1-related familial Alzheimer's disease.

    Chelban V, Breza M, Szaruga M, et al.

    Alzheimer's & dementia (Amsterdam, Netherlands) 2021; (13(1)):e12186 doi:10.1002/dad2.12186.

    PMID: 33969176
  16. 16

    A Case of Early-Onset Alzheimer's Disease Mimicking Schizophrenia in a Patient with Presenilin 1 Mutation (S170P).

    Kim HR, Jang JH, Ham H, et al.

    Journal of Alzheimer's disease : JAD 2021; (83(3)):1025-1031 doi:10.3233/JAD-210650.

    PMID: 34366354
  17. 17

    ApoE3 Christchurch and tau interaction as a protective mechanism against Alzheimer's disease.

    Perez-Corredor P, Arevalo-Alquichire S, Mazzarino RC, et al.

    Alzheimer's & dementia : the journal of the Alzheimer's Association 2025; (21(7)):e70396 doi:10.1002/alz.70396.

    PMID: 40637118
  18. 18

    Resilience to autosomal dominant Alzheimer's disease in a Reelin-COLBOS heterozygous man.

    Lopera F, Marino C, Chandrahas AS, et al.

    Nature medicine 2023; (29(5)):1243-1252 doi:10.1038/s41591-023-02318-3.

    PMID: 37188781
  19. 19

    Heparan sulfate modified proteins affect cellular processes central to neurodegeneration and modulate presenilin function.

    Schultheis N, Connell A, Kapral A, et al.

    bioRxiv : the preprint server for biology 2024; doi:10.1101/2024.01.23.576895.

    PMID: 38328107
  20. 20

    Protective Genes Against Alzheimer's Disease: Case Review and Therapeutic Implications.

    Hossain N, Jeong Y

    Dementia and neurocognitive disorders 2025; (24(2)):75-90 doi:10.12779/dnd.2025.24.2.75.

    PMID: 40321438

This page explains the genetics and biology of ADAD for educational purposes only. Always consult a genetic counselor or neurologist to discuss genetic testing, family history, and personal health risks.

Get notified when new evidence is published on Early-onset autosomal dominant Alzheimer disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.